1Rammew PB, Zannad F. Eplernone, a selective aldlosterone blocker in patients with left ventricular dysfunction after myocardial infarction[J]. N Engl J Med,2003,348 : 1309 - 1321
2Zannad F, Alla F, Dousset B, et al. Limitation of excessive matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure [J].Circulation, 2000, 102: 2700 - 2706
3Yalcin AU,Dincer M,Aalan V,et al. Effect of spironolactone on impaired fibrinolysis of hypertensive patient's[J]. Kidney Blood Press Res, 2002,25 : 260 - 264
4Jaffe IZ,Mendelsohn ME. Angiotensin Ⅱ and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells[J].Cire Res,2005,96:643
5Goodfriend TL, Egan BM, Kelley DE. Plasma aldosterone,plasma lipoproteins, obesity and insulin resistance in humans[J]. Prostaglandins Leukot Essent Fatty Acids, 1999,60 :401 - 405
6Goodfriend TL, Kelley DE, Goodpaster BH, et al. Visceral obesity and insulin resistance are associated with plasma aldosterone levels in women[J]. Obes Res,1999,7:355 - 362
7Arvo H, Richard R, Lars L, et al. Serum aldosterone changes during hyperinsulinemia are correlated to body mass index and insulin sensitivity in patients with essential hypertension[J].J Hypertens, 2001, 19 : 107 - 112
8Manrique C,Last ra G,Whaley- Connell A,et al. Hypertension and the cardiometabolic syndrome [J]. J Clin Hypertens, 2005,7 : 471 - 476
9Cook SA, Aitman T, Naoumova RP. Therapy insight: heart disease and the insulin - resistant patient[J]. Nat Clin Pract Cardiovasw Med,2005,2: 252 - 260
10Lind L,Reneland R, Andersson PE, et al. Insulin resistance in essential hypertension is related to plasma renin activity[J]. J Hum Hypertens, 1998,12 : 379 - 382
